Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Supernus' Shocking Dilution
Motley Fool
Saturday, December 1, 2012 - 9:55am
tags:
Supernus Pharmaceuticals
Amarin's Big Initiation
Motley Fool
Saturday, December 1, 2012 - 9:54am
tags:
Amarin
A Winning Long-Term Growth Pick
Motley Fool
Saturday, December 1, 2012 - 9:53am
tags:
JNJ
Drugmaker Ranbaxy halts generic Lipitor production
Yahoo/AP
Saturday, December 1, 2012 - 9:52am
tags:
Ranbaxy, Lipitor, generics
Endo Health Sues FDA Over Safety of Painkiller Opana
Bloomberg
Saturday, December 1, 2012 - 9:36am
tags:
Endo, Opana, pain management
Is This Dividend Pharma Stock Going Against the Grain?
Motley Fool
Saturday, December 1, 2012 - 9:35am
tags:
Merck
Alimera Sciences shares fall on UK price setback
Yahoo/AP
Saturday, December 1, 2012 - 9:34am
tags:
Alimera, Iluvien, macular degeneration
Long MannKind's Afrezza: Shares Versus A Bull Call Spread
Seeking Alpha
Saturday, December 1, 2012 - 9:33am
tags:
MannKind, Afrezza, inhaled insulin, diabetes, type 1 diabetes, type 2 diabetes
3 Humongous Health-Care Stocks This Week
Motley Fool
Saturday, December 1, 2012 - 9:30am
tags:
Acadia, Cadence Pharmaceuticals, Amicus Therapeutics
Buy, Sell, or Hold: Sarepta Therapeutics
Motley Fool
Saturday, December 1, 2012 - 9:28am
tags:
Sarepta Therapeutics, Duchenne Muscular Dystrophy, muscular dystrophy
Teva provides weak '13 outlook
Yahoo/Investor's Business Daily
Saturday, December 1, 2012 - 9:27am
tags:
Teva Pharmaceuticals
Exelixis' Crowning Achievement
Motley Fool
Saturday, December 1, 2012 - 9:26am
tags:
Exelixis, cabozantinib, Cometriq, thyroid cancer, medullary thyroid cancer
Will Sarepta Receive Accelerated Approval?
Motley Fool
Saturday, December 1, 2012 - 9:25am
tags:
Sarepta, eteplirsen, muscular dystrophy, Duchenne Muscular Dystrophy
Will Merck's Odanacatib Sufficiently Fill Singulair's Void?
Motley Fool
Saturday, December 1, 2012 - 9:23am
tags:
Merck, Odanacatib, osteoporosis
Questcor Pharmaceuticals Inc.: Today's Featured Health Care Laggard
The Street
Saturday, December 1, 2012 - 9:22am
tags:
Questcor Pharmaceuticals
Celgene Corporatio: Today's Featured Drugs Laggard
The Street
Saturday, December 1, 2012 - 9:21am
tags:
Celgene
Hedge Funds Are Buying These 5 Healthcare Stocks With Heavy Short Covering
Seeking Alpha
Saturday, December 1, 2012 - 9:19am
tags:
Affymax, Genomic Health, Incyte, Infinity Pharmaceuticals, MAP Pharmaceuticals
Shares Of BioCryst Pop On Merger Termination, But Gains Are Temporary
Seeking Alpha
Friday, November 30, 2012 - 4:02pm
tags:
Biocryst, M&A, Presidio
J&J Wins Reversal of $1.1 Million Levaquin Punitive Award
Bloomberg
Friday, November 30, 2012 - 4:00pm
tags:
JNJ, Levaquin
Celgene, NPS Pharmaceuticals, Amarin, J&J, Medivation Among Stocks to Watch in December
Minyanville
Friday, November 30, 2012 - 12:18pm
tags:
NPS Pharmaceuticals, Medivation, JNJ, Celgene, Amarin

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.